[Evaluation of the survival of bone marrow mononucleate cells transplanted in a rat model of striatal lesion with quinolinic acid]. / Evaluacion de la supervivencia de las células mononucleadas de la médula ósea trasplantadas en un modelo de ratas con lesión estriatal por ácido quinolínico.

INTRODUCTION: Transplant is one of the alternatives available for the treatment of neurodegenerative diseases aimed at replacing the cells lost during the course of the disease. One promising source of cells for the development of transplants could be the mononucleate cells from bone marrow. AIMS. The purpose of this study was to study the capacity of bone marrow mononucleate cells to survive the transplant process, and to search for a method that enables tracking of these cells in vivo once they have been implanted. MATERIALS AND METHODS: Bone marrow mononucleate cells were extracted from the femur of rats by means of a Ficoll-Hypaque gradient. The cells under study were modified genetically with an adenovirus that expresses the PFV or which are marked with Hoechst dye. The marked cells were implanted in the striatum of rats with lesions caused by quinolinic acid. RESULTS: The viability of the genetically modified cells was low, whereas that of the cells marked with Hoechst dye was above 90%. The implanted cells survived the transplant at least a month and dispersed away from the site of entry towards the corpus callosum and cortex. CONCLUSIONS: We consider that the use of Hoechst dye offers more advantages for tracking these cells in vivo. Mononucleate cells have a number of characteristics that allow them to be included as candidate sources of cells for the treatment of neurodegenerative diseases.

Evaluación de la supervivencia de las células mononucleadas de la médula ósea trasplantadas en un modelo de ratas de lesión estriatal con ácido quinolínico / Evaluation of the survival of bone marrow mononucleate cells transplanted in a rat model of striatal lesion with quinolinic acid

Introducción. El trasplante es una de las alternativas para el tratamiento de enfermedades neurodegenerativas, y está encaminado hacia el reemplazo de las células perdidas durante el desarrollo de la enfermedad. Una fuente celular prometedora para el desarrollo de los trasplantes podrían ser las células mononucleadas de la médula ósea. Objetivo. Estudiar la capacidad de las células mononucleadas de la médula ósea de sobrevivir al trasplante y buscar un método que permita el seguimiento de estas células in vivo una vez implantadas. Materiales y métodos. Las células mononucleadas fueron extraídas del fémur de ratas mediante un gradiente de Ficoll-Hypaque. Las células objeto de estudio fueron modificadas genéticamente con un adenovirus que expresa la PFV o marcadas con el reactivo de Hoechst. Las células marcadas se implantaron en el estriado de ratas lesionadas con ácido quinolínico. Resultados. La viabilidad de las células modificadas genéticamente fue baja, mientras que la de las células marcadas con el reactivo de Hoechst fue superior al 90 por ciento. Las células implantadas sobrevivieron al trasplante al menos un mes y se dispersaron desde el sitio de entrada hacia el cuerpo calloso y la corteza. Conclusiones. Consideramos más ventajoso el uso del reactivo de Hoechst para el seguimiento de estas células in vivo. Las células mononucleadas tienen características que les permiten formar parte de las fuentes celulares candidatas para el tratamiento de las enfermedades neurodegenerativas(AU)

Introduction: Transplant is one of the alternatives available for the treatment of neurodegenerative diseases aimed at replacing the cells lost during the course of the disease. One promising source of cells for the development of transplants could be the mononucleate cells from bone marrow. AIMS. The purpose of this study was to study the capacity of bone marrow mononucleate cells to survive the transplant process, and to search for a method that enables tracking of these cells in vivo once they have been implanted. MATERIALS AND METHODS: Bone marrow mononucleate cells were extracted from the femur of rats by means of a Ficoll-Hypaque gradient. The cells under study were modified genetically with an adenovirus that expresses the PFV or which are marked with Hoechst dye. The marked cells were implanted in the striatum of rats with lesions caused by quinolinic acid. RESULTS: The viability of the genetically modified cells was low, whereas that of the cells marked with Hoechst dye was above 90percent. The implanted cells survived the transplant at least a month and dispersed away from the site of entry towards the corpus callosum and cortex. CONCLUSIONS: We consider that the use of Hoechst dye offers more advantages for tracking these cells in vivo. Mononucleate cells have a number of characteristics that allow them to be included as candidate sources of cells for the treatment of neurodegenerative diseases

Evaluación de la supervivencia de las células mononucleadas de la médula ósea trasplantadas en un modelo de ratas con lesión estriatal por ácido quinolínico / Evaluation of the survival of bone marrow mononucleate cells transplanted in a rat model of striatal lesion with quinolinic acid

Introducción. El trasplante es una de las alternativas para el tratamiento de enfermedades neurodegenerativas, y está encaminado hacia el reemplazo de las células perdidas durante el desarrollo de la enfermedad. Una fuente celular prometedora para el desarrollo de los trasplantes podrían ser las células mononucleadas de la médula ósea. Objetivo. Estudiar la capacidad de las células mononucleadas de la médula ósea de sobrevivir al trasplante y buscar un método que permita el seguimiento de estas células in vivo una vez implantadas. Materiales y métodos. Las células mononucleadas fueron extraídas del fémur de ratas mediante un gradiente de Ficoll-Hypaque. Las células objeto de estudio fueron modificadas genéticamente con un adenovirus que expresa la PFV o marcadas con el reactivo de Hoechst. Las células marcadas se implantaron en el estriado de ratas lesionadas con ácido quinolínico. Resultados. La viabilidad de las células modificadas genéticamente fue baja, mientras que la de las células marcadas con el reactivo de Hoechst fue superior al 90%. Las células implantadas sobrevivieron al trasplante al menos un mes y se dispersaron desde el sitio de entrada hacia el cuerpo calloso y la corteza. Conclusiones. Consideramos más ventajoso el uso del reactivo de Hoechst para el seguimiento de estas células in vivo. Las células mononucleadas tienen características que les permiten formar parte de las fuentes celulares candidatas para el tratamiento de las enfermedades neurodegenerativas

Introduction. Transplant is one of the alternatives available for the treatment of neurodegenerative diseases aimed at replacing the cells lost during the course of the disease. One promising source of cells for the development of transplants could be the mononucleate cells from bone marrow. Aims. The purpose of this study was to study the capacity of bone marrow mononucleate cells to survive the transplant process, and to search for a method that enables tracking of these cells in vivo once they have been implanted. Materials and methods. Bone marrow mononucleate cells were extracted from the femur of rats by means of a Ficoll-Hypaque gradient. The cells under study were modified genetically with an adenovirus that expresses the PFV or which are marked with Hoechst dye. The marked cells were implanted in the striatum of rats with lesions caused by quinolinic acid. Results. The viability of the genetically modified cells was low, whereas that of the cells marked with Hoechst dye was above 90%. The implanted cells survived the transplant at least a month and dispersed away from the site of entry towards the corpus callosum and cortex. Conclusions. We consider that the use of Hoechst dye offers more advantages for tracking these cells in vivo. Mononucleate cells have a number of characteristics that allow them to be included as candidate sources of cells for the treatment of neurodegenerative diseases

[Stromal cell transplant in the 6-OHDA lesion model]. / Trasplante de células estromales en el modelo de lesión por 6-OHDA.

INTRODUCTION: A good deal of evidence currently exists to show that transplanting foetal mesencephalic tissue can produce symptomatic benefits both in patients and in disease models. Nevertheless, the technical and ethical difficulties involved in obtaining enough suitable foetal cerebral tissue have been a serious obstacle to its application. Stromal cells derived from bone marrow, due to their potential capacity to generate different types of cells, could be an ideal source of material for cell restoration in neurodegenerative diseases. AIMS: Our aim was to evaluate the effect of transplanting stromal cells derived from bone marrow on the behaviour of 6-OHDA rats, when they are inserted into the striatum. MATERIAL AND METHODS: In this study we used rats with a lesion in the substantia nigra induced by 6-hydroxydopamine, divided into several experimental groups. Rotary activity induced by D-amphetamine (5 mg/kg, intraperitoneally) was evaluated before and throughout the three months following the transplant in all the experimental groups, except in the group of healthy controls. Hemiparkinsonian rats received a total of 350 000 foetal ventral mesencephalic cells and 8 x 10(4) stromal cells/microL, which were implanted in the striatum. RESULTS AND CONCLUSIONS: Animals with stromal cells transplanted in the body of the striatum significantly reduced the number of turns induced by amphetamine (p < 0.05); yet this reduction was not greater than that induced by foetal mesencephalic cell transplants. We were also unable to demonstrate any significant improvement in the motor skills of the forelimbs.

Trasplante de células estromales en el modelo de lesión por 6-OHDA / Stromal cell transplant in the 6-OHDA lesion model

Introducción. En la actualidad, existe un cúmulo de evidencias de que el trasplante de tejido mesencefálico fetal puede producir un beneficio sintomático tanto en los pacientes con enfermedad de Parkinson como en los modelos de la enfermedad. Sin embargo, las dificultades técnicas y éticas en la obtención de tejido cerebral fetal apropiado y en cantidad suficiente ha dificultado su aplicación. Las células estromales derivadas de médula ósea, debido a su potencialidad para generar diferentes tipos de células, podrían ser una fuente ideal para la restauración celular en las enfermedades neurodegenerativas. Objetivo. Evaluar el efecto del trasplante de células estromales derivadas de médula ósea sobre la conducta de ratas con lesión por 6-OHDA, cuando se realiza en el estriado. Materiales y métodos. Se utilizaron ratas con lesión de la sustancia negra inducida por la 6-OHDA, divididas en varios grupos experimentales. La actividad rotatoria inducida por D-anfetamina (5 mg/kg intraperitonialmente) se evaluó antes y en los tres meses posteriores al trasplante en todos los grupos experimentales, excepto en el grupo de controles sanas. Las ratas hemiparkinsonianas recibieron un total de 350.000 células de mesencéfalo ventral fetal y 8 × 104 células estromales/µL, las cuales se implantaron en el estriado. Resultados y conclusiones. Los animales con trasplante de células estromales en el cuerpo estriado redujeron significativamente el número de vueltas inducidas por anfetamina (p < 0,05); sin embargo, esta reducción no fue mayor que la inducida por los trasplantes de células mesencefálicas fetales. Por otro lado, no fue posible demostrar una mejoría significativa de las habilidades motoras de las extremidades anteriores (AU)

Introduction. A good deal of evidence currently exists to show that transplanting foetal mesencephalic tissue can produce symptomatic benefits both in patients and in disease models. Nevertheless, the technical and ethical difficulties involved in obtaining enough suitable foetal cerebral tissue have been a serious obstacle to its application. Stromal cells derived from bone marrow, due to their potential capacity to generate different types of cells, could be an ideal source of material for cell restoration in neurodegenerative diseases. Aims. Our aim was to evaluate the effect of transplanting stromal cells derived from bone marrow on the behaviour of 6-OHDA rats, when they are inserted into the striatum. Materials and methods. In this study we used rats with a lesion in the substantia nigra induced by 6-hydroxydopamine, divided into several experimental groups. Rotary activity induced by D-amphetamine (5 mg/kg, intraperitoneally) was evaluated before and throughout the three months following the transplant in all the experimental groups, except in the group of healthy controls. Hemiparkinsonian rats received a total of 350,000 foetal ventral mesencephalic cells and 8 × 104 stromal cells/µL, which were implanted in the striatum. Results and conclusions. Animals with stromal cells transplanted in the body of the striatum significantly reduced the number of turns induced by amphetamine (p < 0.05); yet this reduction was not greater than that induced by foetal mesencephalic cell transplants. We were also unable to demonstrate any significant improvement in the motor skills of the forelimbs (AU)

Trasplante de células estromales en el modelo de lesión por 6-OHDA / Stromal cell transplant in the 6-OHDA lesion model

A good deal of evidence currently exists to show that transplanting foetal mesencephalic tissue can produce symptomatic benefits both in patients and in disease models. Nevertheless, the technical and ethical difficulties involved in obtaining enough suitable foetal cerebral tissue have been a serious obstacle to its application. Stromal cells derived from bone marrow, due to their potential capacity to generate different types of cells, could be an ideal source of material for cell restoration in neurodegenerative diseases. AIMS: Our aim was to evaluate the effect of transplanting stromal cells derived from bone marrow on the behaviour of 6-OHDA rats, when they are inserted into the striatum(AU)

[Bone marrow stromal cells. An alternative source of restorative therapy in degenerative diseases of the central nervous system]. / Células estromales de la médula ósea: una fuente terapéutica alternativa en la restauración de enfermedades degenerativas del sistema nervioso central.

AIMS: The aim of this study is to describe the capacity of bone marrow cells to limit or slow down the damage and chronic neuronal degeneration produced by degenerative diseases of the central nervous system (CNS), as well as the potential capacity of the method to provide other substances or genetic material. DEVELOPMENT: The search for new sources of cells that maintain the ability to divide and distinguish themselves from different cellular phenotypes opens up huge new opportunities in the restorative therapy of these clinical entities. Bone marrow cells, and especially stromal stem cells, have been seen to conserve a high capacity to distinguish and originate different strains of characteristic brain cells (neurons, astrocytes, and glial cells), and also the capacity to restore the population of stem cells when they are stimulated in a suitable fashion. CONCLUSIONS: Future experimental studies will be aimed at searching for new ways to enhance the composition, viability and differentiation of the cells to be implanted and will evaluate their effects on diseases of the CNS.

Células estromales de la médula ósea: una fuente terapéutica alternativa en la restauración de enfermedades degenerativas del sistema nervioso central / Bone morrow stromal cells. An alternative source of restorative therapy in degenerative diseases of the central nervous system

Objetivo. Demostrar las capacidades de las células de la médula ósea para limitar o desacelerar el daño y la degeneración neuronal crónica que se producen en las enfermedades degenerativas del sistema nervioso central (SNC), además de la potencialidad del método para suministrar otras sustancias o material genético. Desarrollo. La búsqueda de nuevas fuentes de células que conserven la capacidad de dividirse y diferenciarse hacia distintos fenotipos celulares, abre enormes oportunidades en el tratamiento restaurador de estas entidades. En este sentido, las células de la médula ósea, especialmente las células madre estromales, han demostrado que conservan un alto potencial de diferenciación para originar distintas estirpes celulares características del cerebro (neuronas, astrocitos y glías), así como la capacidad de restablecer la población de células madre cuando se estimulan adecuadamente. Conclusiones. Los futuros estudios experimentales tendrán como propósito la búsqueda de nuevas vías para mejorar la composición, viabilidad y diferenciación de las células que se implanten y evaluarán su efecto sobre las enfermedades del SNC (AU)

Aims. The aim of this study is to describe the capacity of bone marrow cells to limit or slow down the damage and chronic neuronal degeneration produced by degenerative diseases of the central nervous system (CNS), as well as the potential capacity of the method to provide other substances or genetic material. Development. The search for new sources of cells that maintain the ability to divide and distinguish themselves from different cellular phenotypes opens up huge new opportunities in the restorative therapy of these clinical entities. Bone marrow cells, and especially stromal stem cells, have been seen to conserve a high capacity to distinguish and originate different strains of characteristic brain cells (neurons, astrocytes, and glial cells), and also the capacity to restore the population of stem cells when they are stimulated in a suitable fashion. Conclusions. Future experimental studies will be aimed at searching for new ways to enhance the composition, viability and differentiation of the cells to be implanted and will evaluate their effects on diseases of the CNS (AU)

[Ex vivo gene therapy in the treatment of Parkinson s disease]. / Terapia génica ex vivo en el tratamiento de la Enfermedad de Parkinson.

OBJECTIVE: Taking into account the growing development and application of in vivo and ex vivo gene therapy in neurodegenerative disorders we review this kind of therapy applications in Parkinson s disease. DEVELOPMENT: Gene therapy carried out to this illness includes the liberation of genes encoding biosynthetic enzymes for dopamine synthesis: tyrosine hydroxylase, AADC and GTP cyclohydrolase and neurotrophic factors like GDNF which promotes the survival and maintenance of dopamin rgic neurons. Ex vivo gene therapy allows the control of the gene transfer before implantation, however one of the fundamental problems of this procedure is given by the immunologic rejection, so the use of autologous sources is recommended. CONCLUSIONS: Ex vivo gene therapy is advantageous in relation to in vivo gene therapy because it allows the control of gene transfer before the implantation; looking for cellular sources of neural origin or pluripotent stem cells which can be differenciated toward a wanted cellular type in order to achieve the structural and functional integration of the cells implanted in the central nervous system are recommended; however it becomes necessary the development of vectors of new generation to avoid biosafety problems involved in the gene therapy.

Terapia génica ex vivo en el tratamiento de la enfermedad de Parkinson / Ex vivo gene therapy in the treatment of Parkinson´s disease

Objetivo. Teniendo en cuenta el creciente desarrollo y aplicación de la terapia génica tanto in vivo como ex vivo en las enfermedades neurodegenerativas, se revisan las aplicaciones de este tipo de estrategia en la enfermedad de Parkinson. Desarrollo. La terapia génica aplicable a esta enfermedad incluye la introducción de los genes que codifican enzimas que intervienen en la ruta biosintética de la dopamina: tirosina hidroxilasa, AADC y GTP ciclohidrolasa y factores neurotróficos como el GDNF, que promueve la supervivencia y mantenimiento de las neuronas dopaminérgicas. La terapia génica ex vivo permite el control del proceso de transferencia génica antes del proceso de implantación celular; sin embargo, uno de los problemas fundamentales de este procedimiento está dado por el rechazo inmunológico, por lo que se recomienda el uso de fuentes autólogas. Conclusiones. La terapia génica ex vivo presenta ventajas considerables en relación a la terapia in vivo, pues permite mantener el control de la transferencia génica antes del proceso de implantación celular; se recomienda buscar fuentes celulares de origen neural o células madres pluripotentes a las cuales se les puede inducir la diferenciación hacia el tipo celular deseado y , de esta manera, lograr la integración estructural y funcional de las células implantadas al sistema nervioso central. Sin embargo, se hace necesario el desarrollo de vectores de nueva generación que permitan solucionar los problemas de bioseguridad implícitos al utilizar la terapia génica (AU)